Figure 5.

Distribution of the studied patient cohort within current classifications and the power of Cx26 and Cx46 expression to discriminate good and poor prognostic groups within the equivocal categories of NSABP, Miller-Payne G, Sataloff T, EWGBSP TR and MDAAC CPS-EG systems that are used for assessing response to neoadjuvant chemotherapy (A). Both high Cx46 levels and low Cx26 levels correlate with good prognosis (B).

Teleki et al. BMC Cancer 2013 13:50   doi:10.1186/1471-2407-13-50
Download authors' original image